stocks logo

KYMR Valuation

Kymera Therapeutics Inc
$
40.730
+0.86(2.157%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

KYMR Relative Valuation

KYMR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KYMR is overvalued; if below, it's undervalued.

Historical Valuation

Kymera Therapeutics Inc (KYMR) is now in the Fair zone, suggesting that its current forward PS ratio of 41.91 is considered Fairly compared with the five-year average of -18.20. The fair price of Kymera Therapeutics Inc (KYMR) is between 20.21 to 40.93 according to relative valuation methord.
Relative Value
Fair Zone
20.21-40.93
Current Price:40.73
Fair
-10.04
PE
1Y
3Y
5Y
Trailing
Forward
-5.97
EV/EBITDA
Kymera Therapeutics Inc. (KYMR) has a current EV/EBITDA of -5.97. The 5-year average EV/EBITDA is -17.12. The thresholds are as follows: Strongly Undervalued below -55.62, Undervalued between -55.62 and -36.37, Fairly Valued between 2.13 and -36.37, Overvalued between 2.13 and 21.38, and Strongly Overvalued above 21.38. The current Forward EV/EBITDA of -5.97 falls within the Historic Trend Line -Fairly Valued range.
-5.08
EV/EBIT
Kymera Therapeutics Inc. (KYMR) has a current EV/EBIT of -5.08. The 5-year average EV/EBIT is -7.07. The thresholds are as follows: Strongly Undervalued below -90.67, Undervalued between -90.67 and -48.87, Fairly Valued between 34.73 and -48.87, Overvalued between 34.73 and 76.53, and Strongly Overvalued above 76.53. The current Forward EV/EBIT of -5.08 falls within the Historic Trend Line -Fairly Valued range.
41.91
PS
Kymera Therapeutics Inc. (KYMR) has a current PS of 41.91. The 5-year average PS is 31.57. The thresholds are as follows: Strongly Undervalued below 4.92, Undervalued between 4.92 and 18.25, Fairly Valued between 44.89 and 18.25, Overvalued between 44.89 and 58.21, and Strongly Overvalued above 58.21. The current Forward PS of 41.91 falls within the Historic Trend Line -Fairly Valued range.
-13.86
P/OCF
Kymera Therapeutics Inc. (KYMR) has a current P/OCF of -13.86. The 5-year average P/OCF is -28.88. The thresholds are as follows: Strongly Undervalued below -112.71, Undervalued between -112.71 and -70.79, Fairly Valued between 13.03 and -70.79, Overvalued between 13.03 and 54.94, and Strongly Overvalued above 54.94. The current Forward P/OCF of -13.86 falls within the Historic Trend Line -Fairly Valued range.
-11.24
P/FCF
Kymera Therapeutics Inc. (KYMR) has a current P/FCF of -11.24. The 5-year average P/FCF is -17.86. The thresholds are as follows: Strongly Undervalued below -46.90, Undervalued between -46.90 and -32.38, Fairly Valued between -3.34 and -32.38, Overvalued between -3.34 and 11.18, and Strongly Overvalued above 11.18. The current Forward P/FCF of -11.24 falls within the Historic Trend Line -Fairly Valued range.
Kymera Therapeutics Inc (KYMR) has a current Price-to-Book (P/B) ratio of 2.90. Compared to its 3-year average P/B ratio of 3.25 , the current P/B ratio is approximately -10.99% higher. Relative to its 5-year average P/B ratio of 4.45, the current P/B ratio is about -34.93% higher. Kymera Therapeutics Inc (KYMR) has a Forward Free Cash Flow (FCF) yield of approximately -9.39%. Compared to its 3-year average FCF yield of -9.63%, the current FCF yield is approximately -2.52% lower. Relative to its 5-year average FCF yield of -6.68% , the current FCF yield is about 40.45% lower.
2.90
P/B
Median3y
3.25
Median5y
4.45
-9.39
FCF Yield
Median3y
-9.63
Median5y
-6.68

Competitors Valuation Multiple

The average P/S ratio for KYMR's competitors is 26.95, providing a benchmark for relative valuation. Kymera Therapeutics Inc Corp (KYMR) exhibits a P/S ratio of 41.91, which is 55.52% above the industry average. Given its robust revenue growth of -55.26%, this premium appears unsustainable.

Performance Decomposition

1Y
3Y
5Y
Market capitalization of KYMR decreased by 15.78% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -163.98 to -667.60.
The secondary factor is the Revenue Growth, contributed -55.26%to the performance.
Overall, the performance of KYMR in the past 1 year is driven by Margin Expansion. Which is more sustainable.
-55.26%
25.65M → 11.48M
Revenue Growth
+
307.12%
-163.98 → -667.60
Margin Expansion
+
-267.64%
6.84 → -11.47
P/E Change
=
-15.78%
48.36 → 40.73
Mkt Cap Growth

FAQ

arrow icon

Is Kymera Therapeutics Inc (KYMR) currently overvalued or undervalued?

Kymera Therapeutics Inc (KYMR) is now in the Fair zone, suggesting that its current forward PS ratio of 41.91 is considered Fairly compared with the five-year average of -18.20. The fair price of Kymera Therapeutics Inc (KYMR) is between 20.21 to 40.93 according to relative valuation methord.
arrow icon

What is Kymera Therapeutics Inc (KYMR) fair value?

arrow icon

How does KYMR's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Kymera Therapeutics Inc (KYMR) as of Aug 14 2025?

arrow icon

What is the current FCF Yield for Kymera Therapeutics Inc (KYMR) as of Aug 14 2025?

arrow icon

What is the current Forward P/E ratio for Kymera Therapeutics Inc (KYMR) as of Aug 14 2025?

arrow icon

What is the current Forward P/S ratio for Kymera Therapeutics Inc (KYMR) as of Aug 14 2025?